Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Acumen Pharmaceuticals, Inc. ABOS
$5.64
-$0.09 (-1.57%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
238321400.00000000
-
week52high
10.97
-
week52low
3.02
-
Revenue
0
-
P/E TTM
-5
-
Beta
0.00000000
-
EPS
-1.07000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 12:00
Описание компании
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| BTIG | Buy | 15 июл 2022 г. | |
| HC Wainwright & Co. | Buy | 30 июн 2022 г. | |
| Credit Suisse | Outperform | Outperform | 29 мар 2022 г. |
| B of A Securities | Buy | Neutral | 21 янв 2022 г. |
| UBS | Buy | 26 июл 2021 г. | |
| BTIG | Buy | Buy | 05 окт 2022 г. |
| Credit Suisse | Outperform | Outperform | 15 ноя 2022 г. |
| HC Wainwright & Co. | Buy | 02 февр 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Zuga Matt | A | 150800 | 150800 | 17 янв 2023 г. |
| Zuga Matt | A | 109687 | 33500 | 17 янв 2023 г. |
| Barton Russell | A | 120200 | 120200 | 17 янв 2023 г. |
| Barton Russell | A | 26700 | 26700 | 17 янв 2023 г. |
| Meisner Derek M | A | 120800 | 120800 | 17 янв 2023 г. |
| Meisner Derek M | A | 26800 | 26800 | 17 янв 2023 г. |
| OConnell Daniel Joseph | A | 472500 | 472500 | 17 янв 2023 г. |
| OConnell Daniel Joseph | A | 116685 | 114000 | 17 янв 2023 г. |
| Siemers Eric | A | 120200 | 120200 | 17 янв 2023 г. |
| Siemers Eric | A | 26700 | 26700 | 17 янв 2023 г. |
Новостная лента
Acumen Pharmaceuticals, Inc. (ABOS) CEO Daniel O'Connell on Q3 2022 Results - Earnings Call Transcript
Seeking Alpha
14 ноя 2022 г. в 22:34
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Alex Braun - Head IR Daniel O'Connell - President and CEO Eric Siemers - CMO Matt Zuga - CFO and CBO Conference Call Participants Tom Shrader - BTIG Judah Frommer - Credit Suisse Charlie Yang - Bank of America Operator Good day. Thank you for standing by.
Acumen Pharmaceuticals to Report Third Quarter 2022 Financial Results on Nov. 14, 2022
GlobeNewsWire
07 ноя 2022 г. в 16:01
CHARLOTTESVILLE, Va. and CARMEL, Ind., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer's disease, today announced that the Company will report its financial results for the third quarter 2022 on Monday, November 14, 2022. The Company will host a conference call and live audio webcast at 4:30 p.m. ET to provide a business and financial update.
Trading Ideas On The Upcoming CTAD 2022 Conference
Seeking Alpha
02 ноя 2022 г. в 15:27
The Clinical Trials on Alzheimer's Conference will take place from November 29, 2022 to December 2, 2022. Representatives of several listed companies will present data, including Eisai, Anavex, BioVie, Athira Pharma, Cassava Sciences and NervGen.
These Are the Five Best and Worst Performing Small-cap Stocks in September 2022
24/7 Wall Street
21 окт 2022 г. в 20:02
Small-cap stocks are usually young companies that aspire to become large-cap or mega-cap one day.
Why Is Acumen (ABOS) Stock Up 95% Today?
InvestorPlace
28 сент 2022 г. в 12:33
Source: pathdoc / Shutterstock.com Acumen Pharmaceuticals (NASDAQ: ABOS ) stock is rocketing higher on Wednesday but it's not due to any news from the company. Instead, investors have Biogen (NASDAQ: BIIB ) to thank for the increase of ABOS stock's price.